The deal will aim to help the companies discover and develop respiratory and ophthalmology therapies.
Pieris shares rocketed by nearly 50 percent within three hours of the news of the deal dropping.
Pieris will be responsible for discovery research, and Genentech will be responsible for IND-enabling activities, clinical development and commercialization of those programs.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.